The first dose of the COX-2 vaccine was scheduled for release in 2019.

That’s the same year that Congress is expected to pass the Affordable Care Act.

In the meantime, there are several vaccine manufacturers with varying opinions about when to start marketing the vaccine.

One of those, GlaxoSmithKline, says it is planning to begin manufacturing a second vaccine by the end of 2021.

The third is expected in the mid-2020s.

But some vaccine experts say the timing is too soon, given that there are no significant safety concerns.

The third vaccine is a new type of vaccine that uses a “coviral” protein that is produced from a bacteria called Enterobacteriaceae.

The protein is produced by a virus called Cas9.

It has already been approved by the Food and Drug Administration for use in the treatment of pneumonia.

But the new vaccine is being developed for people with weakened immune systems.

It is also being tested in a phase III clinical trial.

“We’re still testing the product in our early phase, but it looks like it’s a good candidate for a potential new vaccine,” said John Miller, a vaccine expert and director of the Vaccine Center at the University of Pittsburgh School of Medicine.

He also cautioned that the timing of the vaccine announcement has been rushed.

“The timing of this is really premature,” Miller said.

“You’d have to go back to 2020 for a serious outbreak to really show up.

That makes it really tough for a vaccine company to put a price on the vaccine at this point.”

Miller, who is also a professor of medicine at Johns Hopkins University, said that until then, “we’re not going to have any real clarity about what the price is.”

While there are indications that the vaccine could be available in early 2021, he said, it’s also possible that the next dose could be delayed until the mid to late 2020s.

The first vaccine has a long shelf life and manufacturers have long had a history of rolling out new vaccines as quickly as possible.

But Miller said he believes the new vaccines are being rushed because the first two vaccines are still undergoing testing and will be able to prove that they are effective.

“I would say that the timeline for a third vaccine could end up being between the beginning of 2020 and the end on 2021,” he said.

The timing also may not matter in states where COVID vaccines are already available.

There are plenty of other vaccines available, and the government already has a large stockpile of COVID vaccine.

But there are other states that are waiting for the new shots to arrive, and some have opted to wait longer for the first shots.

“The question is whether or not we’re going to be able, in the United States, to get COVID vaccination in time for 2020,” said Dr. Thomas Gartner, a professor and head of the immunology department at the Harvard T.H. Chan School of Public Health and the National Institute of Allergy and Infectious Diseases.

The first shots were given to patients at a special site in the New York City borough of Queens.

The second vaccine was given in December at a site in a suburban Boston hospital.

“These were the first to be administered in a public setting,” said Gartners medical director, Dr. Gregory D. Schwartz.

“There was no public health concern and no public outcry about the need for vaccination.”

The third shot was also given in a separate location, but the public was told to remain in their homes.

And a small number of states have opted not to vaccinate people who live in communities that are home to a large number of COV-2 patients.

“You could imagine, especially in the Northeast and some places in the Midwest, that this is a lot of people and a lot is going to get vaccinated,” Gartener said.

And he believes that the delay in the third vaccine will make it harder for some people to get the vaccine if they are in those areas.

“I think the big thing is, for the population that is most at risk, it will be a lot harder to get vaccine, and there will be more people at risk who might have the highest likelihood of getting the vaccine,” he added.

While the vaccine schedule has been in flux, it is likely that the third shot will be administered sooner than later, Miller said, because it’s already been shown to be effective against COVID.

“If the timing in the second vaccine is correct, it should be able… to get into people who are at highest risk for COVID infection,” he noted.

Miller said that while it’s still too soon to predict how many people will get vaccinated, the vaccine is likely to be available.

“They’re going into a population where they are already at high risk, so if they can get that vaccine in the early 2020s, I think it’s likely that we’re not at that risk